Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has earned a consensus rating of "Hold" from the nine analysts that are covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $8.24.

Several equities research analysts recently issued reports on ZNTL shares. Wedbush restated a "neutral" rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, March 28th. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Thursday, March 27th. Wells Fargo & Company lowered their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 30th. Finally, UBS Group cut their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research note on Tuesday, January 28th.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, Director Jan Skvarka purchased 60,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the transaction, the director now owns 149,551 shares of the company's stock, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Ingmar Bruns acquired 20,000 shares of the stock in a transaction on Thursday, February 6th. The shares were acquired at an average price of $2.28 per share, with a total value of $45,600.00. Following the transaction, the insider now directly owns 36,629 shares of the company's stock, valued at $83,514.12. The trade was a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company's stock.

Remove Ads

Institutional Trading of Zentalis Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. Almitas Capital LLC grew its position in Zentalis Pharmaceuticals by 69.3% in the fourth quarter. Almitas Capital LLC now owns 1,626,896 shares of the company's stock worth $4,929,000 after acquiring an additional 665,968 shares in the last quarter. Primecap Management Co. CA lifted its stake in shares of Zentalis Pharmaceuticals by 1.5% in the 4th quarter. Primecap Management Co. CA now owns 1,520,630 shares of the company's stock valued at $4,608,000 after purchasing an additional 22,600 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Zentalis Pharmaceuticals by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 1,312,964 shares of the company's stock worth $3,979,000 after purchasing an additional 20,864 shares during the period. D. E. Shaw & Co. Inc. increased its position in shares of Zentalis Pharmaceuticals by 9.8% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,239,459 shares of the company's stock valued at $3,756,000 after purchasing an additional 110,882 shares during the last quarter. Finally, Integral Health Asset Management LLC purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $3,182,000.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ:ZNTL traded down $0.01 during midday trading on Thursday, hitting $1.16. The company had a trading volume of 996,257 shares, compared to its average volume of 1,538,202. Zentalis Pharmaceuticals has a 12-month low of $1.09 and a 12-month high of $15.79. The company has a fifty day moving average of $1.92 and a two-hundred day moving average of $2.75. The company has a market cap of $83.30 million, a price-to-earnings ratio of -0.47 and a beta of 1.80.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($0.66) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.09. The company had revenue of $26.90 million during the quarter. Research analysts expect that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.